CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Landos Biopharma, Inc. - LABP CFD

    4.08
    2.39%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.09
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026346 %
    Charges from full value of position ($-5.01)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026346%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004124 %
    Charges from full value of position ($0.78)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004124%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Landos Biopharma Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 4.18
    Open* 4.08
    1-Year Change* 946.15%
    Day's Range* 4.08 - 4.27
    52 wk Range 0.21-1.37
    Average Volume (10 days) 72.96K
    Average Volume (3 months) 3.98M
    Market Cap 9.67M
    P/E Ratio -100.00K
    Shares Outstanding 31.17M
    Revenue N/A
    EPS -0.70
    Dividend (Yield %) N/A
    Beta -100.00K
    Next Earnings Date Aug 9, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 4, 2023 4.18 0.03 0.72% 4.15 4.25 4.01
    Dec 1, 2023 4.12 0.02 0.49% 4.10 4.12 4.00
    Nov 30, 2023 4.10 0.18 4.59% 3.92 4.15 3.92
    Nov 29, 2023 4.08 -0.40 -8.93% 4.48 4.48 4.03
    Nov 28, 2023 4.46 0.10 2.29% 4.36 4.46 4.36
    Nov 27, 2023 4.13 0.00 0.00% 4.13 4.41 4.13
    Nov 24, 2023 4.55 0.15 3.41% 4.40 4.75 4.40
    Nov 22, 2023 4.33 0.53 13.95% 3.80 4.33 3.80
    Nov 21, 2023 4.27 0.13 3.14% 4.14 4.38 4.14
    Nov 20, 2023 3.73 -0.15 -3.87% 3.88 3.88 3.73
    Nov 17, 2023 4.03 -0.01 -0.25% 4.04 4.10 3.91
    Nov 16, 2023 3.94 0.08 2.07% 3.86 4.20 3.78
    Nov 15, 2023 3.93 0.16 4.24% 3.77 3.93 3.77
    Nov 14, 2023 3.93 0.05 1.29% 3.88 3.94 3.88
    Nov 13, 2023 3.75 0.14 3.88% 3.61 3.79 3.61
    Nov 10, 2023 3.29 -0.59 -15.21% 3.88 3.88 3.29
    Nov 9, 2023 3.88 -0.22 -5.37% 4.10 4.10 3.88
    Nov 8, 2023 4.12 0.03 0.73% 4.09 4.12 4.00
    Nov 7, 2023 4.09 0.13 3.28% 3.96 4.14 3.95
    Nov 6, 2023 3.88 -0.13 -3.24% 4.01 4.05 3.83

    Landos Biopharma, Inc. Events

    Time (UTC) Country Event
    Thursday, March 21, 2024

    Time (UTC)

    12:30

    Country

    US

    Event

    Q4 2023 Landos Biopharma Inc Earnings Release
    Q4 2023 Landos Biopharma Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 18 0 0 0
    Total Operating Expense 40.561 56.816 30.676 13.29 7.939
    Selling/General/Admin. Expenses, Total 14.581 15.252 5.338 1.478 1.136
    Research & Development 25.68 41.564 25.338 11.812 6.803
    Operating Income -40.561 -38.816 -30.676 -13.29 -7.939
    Interest Income (Expense), Net Non-Operating 0.026 -0.018 0.077 -0.337 -0.11
    Other, Net 1.259 0.412 0.455 0.16 2.005
    Net Income Before Taxes -39.276 -38.422 -30.144 -13.467 -6.044
    Net Income After Taxes -39.276 -38.422 -30.144 -13.467 -6.044
    Net Income Before Extra. Items -39.276 -38.422 -30.144 -13.467 -6.044
    Net Income -39.276 -38.422 -30.144 -13.467 -6.044
    Income Available to Common Excl. Extra. Items -39.276 -38.422 -30.144 -13.467 -6.044
    Income Available to Common Incl. Extra. Items -39.276 -38.422 -30.144 -13.467 -6.044
    Diluted Net Income -39.276 -38.422 -30.144 -13.467 -6.044
    Diluted Weighted Average Shares 40.2549 37.5585 40.1176 39.1632 39.1632
    Diluted EPS Excluding Extraordinary Items -0.97568 -1.02299 -0.75139 -0.34387 -0.15433
    Dividends per Share - Common Stock Primary Issue 0 0
    Diluted Normalized EPS -0.96823 -1.02299 -0.75139 -0.34387 -0.15433
    Revenue 0 18
    Unusual Expense (Income) 0.3
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 6.479 6.513 7.829 11.266 14.953
    Selling/General/Admin. Expenses, Total 3.153 3.099 2.967 4.662 3.853
    Research & Development 3.326 3.414 4.862 6.604 10.8
    Operating Income -6.479 -6.513 -7.829 -11.266 -14.953
    Interest Income (Expense), Net Non-Operating -0.004 0 0 0.025 0.001
    Other, Net 0.449 1.281 -0.067 -0.043 0.088
    Net Income Before Taxes -6.034 -5.232 -7.896 -11.284 -14.864
    Net Income After Taxes -6.034 -5.232 -7.896 -11.284 -14.864
    Net Income Before Extra. Items -6.034 -5.232 -7.896 -11.284 -14.864
    Net Income -6.034 -5.232 -7.896 -11.284 -14.864
    Income Available to Common Excl. Extra. Items -6.034 -5.232 -7.896 -11.284 -14.864
    Income Available to Common Incl. Extra. Items -6.034 -5.232 -7.896 -11.284 -14.864
    Diluted Net Income -6.034 -5.232 -7.896 -11.284 -14.864
    Diluted Weighted Average Shares 64.8423 40.2549 40.2549 40.2549 40.2549
    Diluted EPS Excluding Extraordinary Items -0.09306 -0.12997 -0.19615 -0.28031 -0.36925
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.09306 -0.12997 -0.19615 -0.28031 -0.36179
    Revenue 0 0 0
    Unusual Expense (Income) 0 0 0 0.3
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 45.253 92.146 29.888 50.11 2.492
    Cash and Short Term Investments 44.402 90.88 28.134 49.965 0.359
    Cash & Equivalents 36.64 8.305 2.416 9.808 0.359
    Short Term Investments 7.762 82.575 25.718 40.157 0
    Total Receivables, Net 0.154 0.001 2.092
    Prepaid Expenses 0.851 1.266 0.202 0.144 0.041
    Total Assets 45.253 92.879 30.332 50.48 2.796
    Property/Plant/Equipment, Total - Net 0 0.707 0.444 0.359 0.304
    Property/Plant/Equipment, Total - Gross 0.166 1.248 0.793 0.571 0.413
    Accumulated Depreciation, Total -0.166 -0.541 -0.349 -0.212 -0.109
    Other Long Term Assets, Total 0 0.026 0 0.011 0
    Total Current Liabilities 6.122 16.611 11.034 3.026 1.796
    Accounts Payable 3.435 12.908 8.606 2.048 1.692
    Accrued Expenses 2.687 3.703 1.939 0.978 0.104
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 6.122 16.611 11.31 3.026 1.796
    Total Long Term Debt 0 0 0 0 0
    Total Equity 39.131 76.268 19.022 47.454 1
    Redeemable Preferred Stock 0 0 73.037 73.037 0.032
    Common Stock 0.403 0.403 0.071 0.063 0.059
    Additional Paid-In Capital 172.212 170.241 1.633 0.016 10.044
    Retained Earnings (Accumulated Deficit) -133.427 -94.151 -55.729 -25.585 -9.135
    Other Equity, Total -0.057 -0.225 0.01 -0.077 0
    Total Liabilities & Shareholders’ Equity 45.253 92.879 30.332 50.48 2.796
    Total Common Shares Outstanding 40.2549 40.2549 40.1176 39.1632 39.1632
    Other Current Assets, Total 0 1.398
    Other Current Liabilities, Total 0 0.489
    Other Liabilities, Total 0 0.276
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 51.184 45.253 49.488 58.038 77.359
    Cash and Short Term Investments 50.006 44.402 47.991 55.751 73.796
    Cash & Equivalents 45.244 36.64 28.88 19.241 11.288
    Short Term Investments 4.762 7.762 19.111 36.51 62.508
    Total Receivables, Net
    Prepaid Expenses 1.178 0.851 1.497 2.287 3.563
    Other Current Assets, Total
    Total Assets 51.184 45.253 49.488 58.038 77.61
    Property/Plant/Equipment, Total - Net 0 0 0 0.251
    Total Current Liabilities 4.16 6.122 5.475 6.51 15.507
    Accounts Payable 2.298 3.435 3.204 4.711 9.803
    Accrued Expenses 1.862 2.687 2.271 1.799 5.704
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total
    Total Liabilities 4.16 6.122 5.475 6.51 15.507
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total
    Total Equity 47.024 39.131 44.013 51.528 62.103
    Redeemable Preferred Stock 0 0 0 0
    Common Stock 0.312 0.403 0.403 0.403 0.403
    Additional Paid-In Capital 186.094 172.212 172.016 171.816 171.182
    Retained Earnings (Accumulated Deficit) -139.461 -133.427 -128.195 -120.299 -109.015
    Other Equity, Total 0.079 -0.057 -0.211 -0.392 -0.467
    Total Liabilities & Shareholders’ Equity 51.184 45.253 49.488 58.038 77.61
    Total Common Shares Outstanding 31.1684 40.2549 40.2549 40.2549 40.2549
    Other Long Term Assets, Total 0 0 0
    Property/Plant/Equipment, Total - Gross 0.166 0.575 1.041 1.125
    Accumulated Depreciation, Total -0.166 -0.575 -1.041 -0.874
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -39.276 -38.422 -30.144 -13.467 -6.044
    Cash From Operating Activities -45.771 -27.061 -22.962 -9.874 -6.896
    Cash From Operating Activities 0.577 0.196 0.137 0.103 0.08
    Non-Cash Items 3.002 5.274 1.174 0.213 0.369
    Cash Interest Paid 0 0.027 0.004
    Changes in Working Capital -10.074 5.891 5.871 3.277 -1.301
    Cash From Investing Activities 74.06 -58.706 14.131 -40.325 -0.043
    Capital Expenditures -0.007 -0.44 -0.181 -0.158 -0.043
    Other Investing Cash Flow Items, Total 74.067 -58.266 14.312 -40.167 0
    Cash From Financing Activities 0 91.607 1.518 59.648 5
    Issuance (Retirement) of Stock, Net 0 93.514 1.518 51.668 5
    Issuance (Retirement) of Debt, Net 0 7.98 0
    Net Change in Cash 28.335 5.889 -7.392 9.449 -1.939
    Foreign Exchange Effects 0.046 0.049 -0.079
    Financing Cash Flow Items 0 -1.907
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -6.034 -39.276 -34.044 -26.148 -14.864
    Cash From Operating Activities -8.17 -45.771 -42.072 -34.499 -16.502
    Cash From Operating Activities 0 0.577 0.577 0.577 0.353
    Non-Cash Items 0.256 3.002 2.82 2.238 1.381
    Changes in Working Capital -2.392 -10.074 -11.425 -11.166 -3.372
    Cash From Investing Activities 3.104 74.06 62.589 45.377 19.506
    Capital Expenditures 0 -0.007 -0.007 -0.007 -0.007
    Other Investing Cash Flow Items, Total 3.104 74.067 62.596 45.384 19.513
    Cash From Financing Activities 13.666 0 0 0 0
    Issuance (Retirement) of Stock, Net 13.666 0 0 0 0
    Net Change in Cash 8.604 28.335 20.575 10.936 2.983
    Foreign Exchange Effects 0.004 0.046 0.058 0.058 -0.021
    Financing Cash Flow Items 0

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Landos Biopharma, Inc. Company profile

    About Landos Biopharma Inc

    Landos Biopharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. The Company through its artificial intelligence (AI)-based precision medicine platform, LANCE platform, identifies therapeutic targets based on predictions of immunometabolic function and create therapeutic candidates to engage those targets in areas of unmet medical need. Its platform discovers small molecule therapeutics for patients with autoimmune diseases that targets mechanisms of action, including LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. It identifies novel immunometabolic targets and product candidates across indications, such as ulcerative colitis (UC), Crohn’s disease (CD), eosinophilic esophagitis (EoE), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its Omilancor is an oral, gut restricted LANCL2 agonist in development for the treatment of UC, CD and EoE.

    Financial summary

    BRIEF: For the nine months ended 30 September 2021, Landos Biopharma Inc revenues increased from $0K to $18M. Net loss decreased 3% to $18.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.48 to -$0.57.

    Industry: Biotechnology & Medical Research (NEC)

    1800 Kraft Drive, Suite 216
    24060

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    US100

    15,864.90 Price
    +0.290% 1D Chg, %
    Long position overnight fee -0.0263%
    Short position overnight fee 0.0041%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Gold

    2,019.47 Price
    -0.500% 1D Chg, %
    Long position overnight fee -0.0198%
    Short position overnight fee 0.0116%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    XRP/USD

    0.63 Price
    -0.580% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    BTC/USD

    43,654.85 Price
    +3.670% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading